A new study by the Microbicide Trials Network found no safety concerns with using the dapivirine vaginal ring during all stages of pregnancy. The research provides sufficient evidence that the ring is safe to use throughout pregnancy to protect against HIV, which poses a higher risk than at any other time.
A fast-dissolving insert containing TAF and EVG was found safe and effective in preventing HIV transmission through anal sex. The study delivered high levels of the drugs to rectal tissue and fluid, with potential protection for up to three days after use.
Researchers found dapivirine levels in breast milk to be very low, posing no safety concerns. The study supports the inclusion of breastfeeding populations in global guidelines for the use of the dapivirine vaginal ring for HIV prevention.
The DELIVER study found that the vaginal dapivirine ring posed no safety concerns when used in the third trimester of pregnancy. The study enrolled women at different stages of gestation and reported similar pregnancy outcomes between those using the ring and a placebo.
The REACH study found that nearly all adolescent girls and young women accepted the option of using a monthly dapivirine vaginal ring or daily oral PrEP. Most preferred the ring, but most were able to use their chosen product some or most of the time. The study suggests that choice is crucial for adherence in HIV prevention.
A study found that adolescent girls and young women in Africa consistently used daily oral PrEP and monthly dapivirine vaginal ring to prevent HIV. The results exceeded expectations, with 97% of participants using the products, indicating high acceptability and adherence.
A recent review of over 10,000 medical records from four African countries has shed light on pregnancy and neonatal outcomes, as well as the frequency of various complications. The study's findings will help determine the safety of PrEP and dapivirine ring for HIV prevention in pregnant women.
A 90-day dapivirine ring has passed its first test in a Phase I study, showing promising results for long-acting HIV prevention in cisgender women. The ring achieved higher dapivirine concentrations in blood plasma and vaginal fluid compared to the monthly dapivirine ring, suggesting potential for sustained protection.
The DESIRE study found that efficacy was the strongest determinant of participants' stated modality choice, followed by delivery method and side effects. Participants preferred a douche used 30 minutes before sex with 95% efficacy, offering three to five days of protection.
Researchers report positive results from three Phase I studies on rectal microbicides, including a gel containing dapivirine that was well-tolerated but required higher doses to provide protection. The studies suggest that dosing changes and longer-acting formulations may be necessary for effective HIV prevention through anal sex.
A new 90-day dual-purpose vaginal ring containing dapivirine and levonorgestrel has shown promising results in preventing both HIV and unintended pregnancy. The study found that the ring delivered sustained levels of each drug, likely sufficient for protection against both, with minimal bleeding concerns.
A new study aims to assess the safety of a monthly dapivirine ring and daily oral PrEP in breastfeeding women, who are at high risk of HIV infection. The study, called B-PROTECTED, will enroll up to 200 mothers and their babies in Malawi, South Africa, Uganda, and Zimbabwe.
A monthly vaginal ring containing the antiretroviral drug dapivirine is being considered as a new HIV prevention method for cisgender women in sub-Saharan Africa. The European Medicines Agency has adopted a positive scientific opinion on its use, paving the way for potential approval.
A new study called DELIVER will enroll 750 healthy, HIV-negative pregnant women to test the safety of two HIV prevention methods: a monthly dapivirine vaginal ring and daily Truvada. The study aims to provide much-needed information about these products' safety in pregnant women, an area currently lacking in data.
The HOPE study found that most women accepted the dapivirine ring and used it consistently throughout the year. The study showed a significant reduction in HIV incidence among participants, with an estimated 39% decrease in risk compared to those not offered the ring.
The Microbicide Trials Network is conducting a study to assess the acceptability, tolerability, and adherence of three rectal delivery methods: placebo inserts, suppositories, and douches. The study aims to understand individual preferences for HIV prevention products.
A new study called REACH seeks to understand the safety and acceptability of a daily oral tablet called Truvada (PrEP) and a monthly vaginal ring containing an antiretroviral drug called dapivirine. The study aims to enroll 300 young women and girls ages 16-21 in four African countries, providing them with choices in HIV prevention.
A new 90-day vaginal ring containing tenofovir is being tested for its safety in preventing HIV and herpes simplex virus type 2 (HSV-2) infections. The Phase I study aims to determine the safety of the ring for three months, with results expected mid-2020.
The dapivirine-levonorgestrel ring provided protection against HIV infection and unintended pregnancy for 90 days, with plasma concentrations of levonorgestrel consistent with those required for contraception. The ring was well-tolerated and showed promising results in its first clinical study.
A new study suggests that a monthly vaginal ring releasing dapivirine, an antiretroviral drug, poses minimal risk of developing drug-resistant HIV. The research analyzed plasma samples from women who acquired HIV during the ASPIRE Phase III trial and found no cases of dapivirine-associated resistance.
The HOPE open-label study found that women's risk of acquiring HIV was reduced by more than half, with an incidence rate of 1.9 new infections per 100 participants. Women's adherence to the ring use appears to be higher in HOPE compared to ASPIRE, with 89% indicating regular use.
A study conducted in the US has found that adolescent girls can safely use a dapivirine vaginal ring to prevent HIV. The ring, which contains an antiretroviral drug, was shown to be highly acceptable and easy to use, with high adherence rates among participants.
A US study of the dapivirine ring among lactating women found that the drug is absorbed in very low concentrations into breastmilk. The results support further studies on the safety of the ring during breastfeeding and pregnancy, which are planned to be conducted in Africa.
The Microbicide Trials Network (MTN) starts a Phase I study to test a vaginal ring containing dapivirine and levonorgestrel, aiming to provide protection against HIV and unintended pregnancy. The trial aims to evaluate the safety and effectiveness of the dual-purpose ring.
Participants were highly adherent to using the gel before and after sex (93%) as they were to taking daily oral Truvada (94%). The study found that most participants used the gel 80% of the time or more, suggesting a potential alternative for HIV prevention.
A large HIV prevention trial found that women experiencing intimate partner violence were less likely to use a vaginal ring, with improved adherence after disclosure. Counseling and support can help these women adhere to the ring, improving their protection against HIV.
Researchers found no differences in HIV drug resistance between women using dapivirine and placebo rings in the ASPIRE trial. The dapivirine ring was safe and helped protect against HIV, with an overall risk reduction of 27%.
Researchers found that using the dapivirine ring consistently provided significant protection against HIV, with high adherence associated with better HIV protection. The study's results coincide with the start of the HOPE open-label study, which will gather additional information on the ring's safety and effectiveness.
The HOPE study will build on the ASPIRE trial results, gathering more information on the dapivirine ring's safety and effectiveness in reducing HIV risk. The study aims to understand why the ring works for some women but not others.
A reduced glycerin formulation of tenofovir gel was found safe when used daily and around the time of sex for HIV prevention. Participants were as likely to follow through using the gel with sex as they were taking daily oral PrEP, demonstrating its potential as a rectal microbicide for people at risk of HIV from anal sex.
The dapivirine ring reduced the risk of HIV infection by 27 percent overall among more than 2,600 women in Africa. Women aged 25 and older saw a significant reduction in HIV risk, with some experiencing a cut in risk of over half.
The ASPIRE Phase III trial tested the safety and effectiveness of a vaginal ring containing dapivirine for preventing HIV in women. The study found that women who used the ring experienced reduced risk of HIV infection, paving the way for potential long-acting protection against the disease.
The VOICE trial found that women who used tenofovir gel had a lower risk of HIV, despite overall product non-adherence being high. Tenofovir gel reduced HIV risk by 14.7% for those who used it, but the study as a whole showed products were not effective in preventing HIV.
A sub-study of the VOICE trial found that despite reported high adherence rates, fewer than 30% of women used their assigned HIV prevention products regularly. Women cited fears about product side effects and negative attitudes from peers and community members as reasons for nonuse.
The VOICE trial found that regular use of tenofovir gel reduced the risk of herpes simplex virus type 2 (HSV-2) acquisition by 46 percent. Women who used the gel regularly were 20.2 percent likely to acquire HSV-2 compared to 11.6 percent among those who didn
The ASPIRE trial is testing a vaginal ring containing the antiretroviral drug dapivirine for HIV prevention in women. The study has completed enrollment with 2,629 participants and is expected to conclude by late 2015 or early 2016.
A new analysis confirms that behavioral measures used in the VOICE study did not accurately predict women's use and nonuse of HIV prevention products. Biological measures, such as drug levels in stored samples, provided a more accurate picture of adherence.
A Phase I study of a combination ARV vaginal ring found the ring safe and effective in preventing HIV infection, with dapivirine showing promising results. However, maraviroc, the first entry inhibitor tested as a microbicide, was not as effective and requires further development.
Researchers analyzed data from the VOICE trial and found that women using injectable contraceptive DMPA were more likely to acquire HIV than those using NET-EN. The study also showed a significant difference in HIV risk between DMPA and NET-EN users, particularly among HSV-2 positive women.
A Phase II clinical trial is underway to test the safety and acceptability of a reduced glycerin gel formulation of tenofovir in preventing HIV transmission through unprotected anal sex. The study aims to determine whether rectal microbicides can be used as an additional tool to reduce HIV risk.
A reformulated version of an anti-HIV gel developed for vaginal use was found safe and acceptable by HIV-negative men and women who used it rectally. The study tested a reduced glycerin formulation of tenofovir gel, which showed promise as a microbicide for preventing or reducing the sexual transmission of HIV from unprotected anal sex.
The VOICE study found that daily use of vaginal gel or oral tablets did not prevent HIV in young, unmarried African women. Most participants did not use their assigned products as recommended, resulting in high rates of HIV acquisition among this population.
A recent study found that tenofovir gel achieves substantially higher concentrations of active drug in vaginal tissue than the oral tablet, suggesting it should be highly effective in protecting women against HIV transmitted through vaginal sex. However, this has not been borne out in HIV prevention trials to date.
A large clinical trial testing a vaginal ring containing dapivirine, a potent antiretroviral drug, is underway in Africa to evaluate its safety and effectiveness in preventing HIV transmission among women. The trial aims to enroll 3,500 women across several African countries.
Researchers from Microbicide Trials Network reformulated tenofovir gel to reduce glycerin content, making it safer and more effective for rectal use. The new formulation is three times less likely to cause cells to release water and equally effective against HIV as the original vaginal formulation.
Researchers from the Microbicide Trials Network reported two new findings from HPTN 035 data, presenting contradictory results to previous studies on hormonal contraception and HIV risk. The analysis of nearly 3,000 women found no association between hormonal contraceptive use and increased risk of HIV infection.
A Phase I clinical study has confirmed that a new rectal formulation of tenofovir gel is safe and well-tolerated when used daily for one week. The gel, designed to reduce glycerin levels, showed promise in preventing HIV transmission from anal sex, with high adherence rates among participants.
The VOICE trial has stopped using tenofovir gel due to its lack of effectiveness in preventing HIV. Women enrolled in the study will still participate in the daily use of Truvada, which was found to be effective.
A new vaginal ring combining dapivirine and maraviroc is being evaluated for its safety and effectiveness as an HIV microbicide. The study, MTN-013/IPM 026, aims to assess the ring's ability to prevent HIV infection in women through vaginal sex.
The VOICE trial will continue testing the safety and effectiveness of oral Truvada and tenofovir gel, while discontinuing daily use of oral tenofovir tablets. The trial enrolled 5,029 women across three countries to evaluate the efficacy of ARV-based approaches in preventing HIV transmission.